deferasirox has been researched along with Stroke in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA | 1 |
| Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC | 1 |
| Rempe, DA; Zhao, Y | 1 |
| Alvarez, O; Cohen, AR; Garro, J; Kwiatkowski, JL; Lane, P; Mortier, N; Mueller, B; Nagasubramanian, R; Sarnaik, S; Schultz, W; Thompson, A; Ware, RE; Woods, GM; Yovetich, N | 1 |
3 trial(s) available for deferasirox and Stroke
| Article | Year |
|---|---|
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Chelation Therapy; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Hydroxyurea; Incidence; Iron Chelating Agents; Iron Overload; Male; Pain Measurement; Phlebotomy; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Stroke; Transfusion Reaction; Triazoles; Ultrasonography, Doppler, Transcranial | 2015 |
Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult | 2012 |
1 other study(ies) available for deferasirox and Stroke
| Article | Year |
|---|---|
Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.
Topics: Animals; Astrocytes; Benzoates; Brain; Cyclic AMP Response Element-Binding Protein; Deferasirox; Deferoxamine; Erythropoietin; Extracellular Signal-Regulated MAP Kinases; Gene Deletion; Hypoxia-Inducible Factor 1; Iron Chelating Agents; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Phosphorylation; Proto-Oncogene Proteins c-akt; Stroke; Triazoles | 2011 |